UBS Group’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $806K | Buy |
63,804
+58,712
| +1,153% | +$787K | ﹤0.01% | 5718 |
|
|
2025
Q4 | $80.3K | Sell |
5,092
-10,215
| -67% | -$130K | ﹤0.01% | 7011 |
|
|
2025
Q3 | $183K | Sell |
15,307
-32,731
| -68% | -$262K | ﹤0.01% | 6724 |
|
|
2025
Q2 | $363K | Buy |
48,038
+1,890
| +4% | +$11.4K | ﹤0.01% | 6271 |
|
|
2025
Q1 | $255K | Buy |
46,148
+14,996
| +48% | +$92.6K | ﹤0.01% | 6370 |
|
|
2024
Q4 | $179K | Buy |
31,152
+1,816
| +6% | +$17.4K | ﹤0.01% | 6516 |
|
|
2024
Q3 | $304K | Buy |
29,336
+19,641
| +203% | +$257K | ﹤0.01% | 5560 |
|
|
2024
Q2 | $126K | Sell |
9,695
-10,620
| -52% | -$143K | ﹤0.01% | 6004 |
|
|
2024
Q1 | $355K | Sell |
20,315
-915
| -4% | -$12.1K | ﹤0.01% | 5451 |
|
|
2023
Q4 | $200K | Buy |
21,230
+8,272
| +64% | +$77.1K | ﹤0.01% | 5784 |
|
|
2023
Q3 | $145K | Sell |
12,958
-30,537
| -70% | -$492K | ﹤0.01% | 5595 |
|
|
2023
Q2 | $931K | Buy |
43,495
+33,183
| +322% | +$978K | ﹤0.01% | 4320 |
|
|
2023
Q1 | $417K | Sell |
10,312
-27,704
| -73% | -$1.32M | ﹤0.01% | 4835 |
|
|
2022
Q4 | $1.77M | Buy |
38,016
+35,838
| +1,645% | +$1.63M | ﹤0.01% | 3517 |
|
|
2022
Q3 | $113K | Sell |
2,178
-10,001
| -82% | -$584K | ﹤0.01% | 5607 |
|
|
2022
Q2 | $576K | Sell |
12,179
-13,125
| -52% | -$712K | ﹤0.01% | 4158 |
|
|
2022
Q1 | $1.8M | Sell |
25,304
-15,060
| -37% | -$980K | ﹤0.01% | 3533 |
|
|
2021
Q4 | $3.02M | Buy |
40,364
+9,159
| +29% | +$719K | ﹤0.01% | 3350 |
|
|
2021
Q3 | $1.77M | Buy |
31,205
+20,191
| +183% | +$998K | ﹤0.01% | 3672 |
|
|
2021
Q2 | $485K | Sell |
11,014
-15,216
| -58% | -$745K | ﹤0.01% | 4761 |
|
|
2021
Q1 | $1.29M | Buy |
26,230
+26,136
| +27,804% | +$1.3M | ﹤0.01% | 3997 |
|
|
2020
Q4 | $4K | Buy |
+94
| New | +$4.13K | ﹤0.01% | 7903 |
|
|
2020
Q3 | – | Sell |
-456
| Closed | -$23K | – | 8085 |
|
|
2020
Q2 | $23K | Sell |
456
-4,447
| -91% | -$230K | ﹤0.01% | 6458 |
|
|
2020
Q1 | $252K | Sell |
4,903
-990
| -17% | -$52.8K | ﹤0.01% | 4549 |
|
|
2019
Q4 | $364K | Sell |
5,893
-21,680
| -79% | -$1.34M | ﹤0.01% | 5128 |
|
|
2019
Q3 | $1.66M | Buy |
27,573
+21,376
| +345% | +$1.59M | ﹤0.01% | 3491 |
|
|
2019
Q2 | $523K | Buy |
6,197
+6,069
| +4,741% | +$546K | ﹤0.01% | 4261 |
|
|
2019
Q1 | $13K | Sell |
128
-30,489
| -100% | -$2.73M | ﹤0.01% | 6633 |
|
|
2018
Q4 | $2.17M | Buy |
30,617
+18,296
| +148% | +$1.4M | ﹤0.01% | 2960 |
|
|
2018
Q3 | $1.05M | Buy |
12,321
+7,450
| +153% | +$746K | ﹤0.01% | 3800 |
|
|
2018
Q2 | $565K | Sell |
4,871
-22,898
| -82% | -$2.28M | ﹤0.01% | 4226 |
|
|
2018
Q1 | $2.25M | Buy |
27,769
+25,706
| +1,246% | +$1.98M | ﹤0.01% | 3035 |
|
|
2017
Q4 | $121K | Sell |
2,063
-5,383
| -72% | -$270K | ﹤0.01% | 5227 |
|
|
2017
Q3 | $349K | Buy |
7,446
+7,125
| +2,220% | +$286K | ﹤0.01% | 4483 |
|
|
2017
Q2 | $12K | Buy |
321
+50
| +18% | +$1.6K | ﹤0.01% | 6641 |
|
|
2017
Q1 | $8K | Sell |
271
-8,560
| -97% | -$267K | ﹤0.01% | 6745 |
|
|
2016
Q4 | $296K | Buy |
8,831
+6,176
| +233% | +$177K | ﹤0.01% | 4494 |
|
|
2016
Q3 | $71K | Sell |
2,655
-9,337
| -78% | -$217K | ﹤0.01% | 5224 |
|
|
2016
Q2 | $264K | Buy |
11,992
+11,003
| +1,113% | +$288K | ﹤0.01% | 4352 |
|
|
2016
Q1 | $29K | Sell |
989
-26,640
| -96% | -$742K | ﹤0.01% | 5914 |
|
|
2015
Q4 | $912K | Buy |
27,629
+20,500
| +288% | +$668K | ﹤0.01% | 3481 |
|
|
2015
Q3 | $258K | Buy |
7,129
+6,690
| +1,524% | +$287K | ﹤0.01% | 4434 |
|
|
2015
Q2 | $20K | Buy |
439
+139
| +46% | +$5.41K | ﹤0.01% | 6865 |
|
|
2015
Q1 | $9K | Sell |
300
-4,050
| -93% | -$158K | ﹤0.01% | 7709 |
|
|
2014
Q4 | $221K | Buy |
+4,350
| New | +$195K | ﹤0.01% | 4946 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
UBS Group's ENTA Position: Q1 2026 in Review
UBS Group increased its Enanta Pharmaceuticals (ENTA) stake by 1,153% in Q1 2026, buying an estimated $787K and bringing the position to 63,804 shares worth $806K. The position accounts for ﹤0.01% of the portfolio, ranked #5718.
UBS Group first reported a position in ENTA in Q4 2014 and has held it in 45 quarters since. The position peaked at $3.02M in Q4 2021. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- UBS Group held 63,804 shares of Enanta Pharmaceuticals worth $806K as of Q1 2026.
- UBS Group bought 58,712 Enanta Pharmaceuticals shares in Q1 2026, an estimated $787K.
- Enanta Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5718 holding.
- UBS Group first reported a position in Enanta Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
- UBS Group's Enanta Pharmaceuticals position peaked at $3.02M in Q4 2021.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.